Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.
SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.
严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）是引发 2019 年冠状病毒病（COVID-19）的病原体，于 2019 年末在中国首次出现。自此，它已感染了全球超过 87 万人，并导致超过 4.3 万人死亡。在此，我们讨论了针对 SARS-CoV-2 的治疗和预防干预措施，重点讨论了疫苗的开发及其面临的挑战。疫苗正在迅速开发中，但可能为时过晚，无法影响潜在大流行的第一波疫情。然而，我们可以从中吸取重要的经验教训，为快速出现的病毒开发疫苗。重要的是，如果该病毒在人群中立足，SARS-CoV-2 疫苗对于降低发病率和死亡率将是必不可少的。
